Location History:
- Upsala, SE (1993 - 1996)
- Asaka, JP (2003)
- Saitama, JP (2006)
- Uppsala, SE (1994 - 2011)
- Shiki, JP (2001 - 2011)
- Tokyo, JP (1993 - 2021)
Company Filing History:
19 out of 525 
5 out of 55 
1 out of 71 
Years Active: 1993-2021
Title: Kohei Miyazono: A Pioneer in BMP-Related Therapeutics
Introduction
Kohei Miyazono, based in Uppsala, Sweden, is an accomplished inventor with a remarkable portfolio of 29 patents. His contributions primarily focus on innovative therapeutic agents that target various biological pathways, most notably the BMP signal pathways, which play a crucial role in cell growth and differentiation.
Latest Patents
Among Miyazono's latest inventions is a BMP-signal-inhibiting compound. This cutting-edge small-molecule compound specifically antagonizes BMP signal pathways. Its therapeutic potential lies in its ability to modulate cell growth, differentiation, proliferation, and apoptosis. This invention addresses critical health issues related to BMP signaling, including inflammation, cardiovascular diseases, hematopoietic disorders, cancer, and osteodystrophia, particularly fibrodysplasia ossificans progressiva. His patent also outlines the provision of a pharmaceutical agent designed for the prevention and treatment of diseases linked to BMP signal pathways.
Another significant patent features antibodies that specifically bind to activin receptor-like kinase 3. This discovery involves a new receptor family of activin-like kinases, showcasing novel proteins that exhibit activin/TGF-β-type I receptor functionality. These proteins possess undeniable diagnostic and therapeutic implications, which may include serine/threonine kinase domains critical for their function.
Career Highlights
Miyazono's career is marked by his contributions to the Ludwig Institute for Cancer Research Limited and the Japanese Foundation for Cancer Research. His work in these institutions has significantly advanced our understanding of cancer biology and the interactions of cellular signaling pathways.
Collaborations
Throughout his career, Miyazono has collaborated with notable researchers, including Carl-Henrik Heldin and Peter ten Dijke. These partnerships have further enriched the research landscape, enhancing the development of new therapeutic strategies.
Conclusion
Kohei Miyazono’s extensive work in the fields of cell signaling and therapeutics continues to pave the way for potential breakthroughs in treatment methodologies. His patents reflect a commitment to advancing scientific knowledge and providing solutions for complex medical issues, reinforcing his position as a leading figure in the innovation landscape.